Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

labcorp holdings - LH

LH

Close Chg Chg %
237.88 2.28 0.96%

Closed Market

240.16

+2.28 (0.96%)

Volume: 302.73K

Last Updated:

Nov 21, 2024, 3:59 PM EDT

Trade Now

Company Overview: labcorp holdings - LH

LH Key Data

Open

$236.79

 Day Range

235.01 - 240.80

52 Week Range

191.97 - 247.98

 Market Cap

$19.89B

Shares Outstanding

83.64M

 Public Float

83.35M

Beta

1.05

 Rev. Per Employee

N/A

P/E Ratio

46.05

 EPS

$5.20

Yield

121.09%

 Dividend

$0.72

EX-DIVIDEND DATE

Nov 26, 2024

 SHORT INTEREST

N/A

AVERAGE VOLUME

779.54K

  

LH Performance

1 Week
 
 2.11%
 
1 Month
 
 5.05%
 
3 Months
 
 4.02%
 
1 Year
 
 12.90%
 
5 Years
 
 66.42%
 

LH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 20
Full Ratings ➔

About labcorp holdings - LH

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

LH At a Glance

Labcorp Holdings, Inc.
358 South Main Street
Burlington, North Carolina 27215-5837
Phone 1-336-229-1127 Revenue 12.16B
Industry Medical/Nursing Services Net Income 418.00M
Sector Health Services Employees 67,000
Fiscal Year-end 12 / 2024
View SEC Filings

LH Valuation

P/E Current 46.051
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 47.633
Price to Sales Ratio 1.637
Price to Book Ratio 2.422
Price to Cash Flow Ratio 14.996
Enterprise Value to EBITDA 14.868
Enterprise Value to Sales 2.084
Total Debt to Enterprise Value 0.235

LH Efficiency

Revenue/Employee 181,516.418
Income Per Employee 6,238.806
Receivables Turnover 5.795
Total Asset Turnover 0.66

LH Liquidity

Current Ratio 1.167
Quick Ratio 1.02
Cash Ratio 0.166

LH Profitability

Gross Margin 25.861
Operating Margin 9.24
Pretax Margin 4.678
Net Margin 3.437
Return on Assets 2.056
Return on Equity 4.22
Return on Total Capital 2.742
Return on Invested Capital 2.656

LH Capital Structure

Total Debt to Total Equity 75.609
Total Debt to Total Capital 43.055
Total Debt to Total Assets 35.60
Long-Term Debt to Equity 60.726
Long-Term Debt to Total Capital 34.58
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Labcorp Holdings - LH

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
13.98B 16.12B 14.88B 12.16B
Sales Growth
+20.98% +15.33% -7.72% -18.25%
Cost of Goods Sold (COGS) incl D&A
9.30B 10.87B 10.75B 9.02B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
825.00M 940.00M 828.30M 580.90M
Depreciation
549.60M 570.40M 569.00M 361.10M
Amortization of Intangibles
275.40M 369.60M 259.30M 219.80M
COGS Growth
+8.84% +16.83% -1.06% -16.13%
Gross Income
4.68B 5.25B 4.13B 3.15B
Gross Income Growth
+55.43% +12.34% -21.48% -23.77%
Gross Profit Margin
+33.46% +32.60% +27.73% +25.86%
2020 2021 2022 2023 5-year trend
SG&A Expense
1.71B 1.89B 2.00B 2.02B
Research & Development
- - - -
-
Other SG&A
1.71B 1.89B 2.00B 2.02B
SGA Growth
+8.82% +10.91% +5.41% +1.24%
Other Operating Expense
- - - -
-
Unusual Expense
524.20M 101.10M 355.30M 398.10M
EBIT after Unusual Expense
2.45B 3.26B 1.77B 725.60M
Non Operating Income/Expense
(18.90M) 79.20M (11.00M) 42.90M
Non-Operating Interest Income
10.30M 10.20M 8.90M 28.80M
Equity in Earnings of Affiliates
2.90M 26.50M 5.40M (1.40M)
Interest Expense
207.40M 212.10M 180.30M 199.60M
Interest Expense Growth
-13.83% +2.27% -14.99% +10.70%
Gross Interest Expense
207.40M 212.10M 180.30M 199.60M
Interest Capitalized
- - - -
-
Pretax Income
2.22B 3.13B 1.58B 568.90M
Pretax Income Growth
+100.84% +40.89% -49.38% -64.05%
Pretax Margin
+15.88% +19.39% +10.64% +4.68%
Income Tax
662.10M 747.10M 302.00M 188.50M
Income Tax - Current - Domestic
628.10M 717.40M 229.50M 222.00M
Income Tax - Current - Foreign
81.00M 107.70M 65.30M 44.60M
Income Tax - Deferred - Domestic
(34.80M) (78.30M) 2.40M (94.70M)
Income Tax - Deferred - Foreign
(12.20M) 300.00K 4.80M 16.60M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
2.90M 26.50M 5.40M (1.40M)
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.56B 2.38B 1.28B 380.40M
Minority Interest Expense
900.00K 2.20M 1.50M 1.20M
Net Income
1.56B 2.38B 1.28B 379.20M
Net Income Growth
+88.89% +52.77% -46.20% -70.35%
Net Margin Growth
+11.13% +14.75% +8.60% +3.12%
Extraordinaries & Discontinued Operations
- - - 38.80M
-
Discontinued Operations
- - - 38.80M
-
Net Income After Extraordinaries
1.56B 2.38B 1.28B 418.00M
Preferred Dividends
- - - -
-
Net Income Available to Common
1.56B 2.38B 1.28B 418.00M
EPS (Basic)
15.9928 24.5843 14.0406 4.7991
EPS (Basic) Growth
+90.06% +53.72% -42.89% -65.82%
Basic Shares Outstanding
97.30M 96.70M 91.10M 87.10M
EPS (Diluted)
15.8786 24.3826 13.964 4.7717
EPS (Diluted) Growth
+90.05% +53.56% -42.73% -65.83%
Diluted Shares Outstanding
98.00M 97.50M 91.60M 87.60M
EBITDA
3.79B 4.30B 2.96B 1.70B
EBITDA Growth
+71.61% +13.33% -31.23% -42.36%
EBITDA Margin
+27.15% +26.68% +19.88% +14.02%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 263.688
Number of Ratings 20 Current Quarters Estimate 3.40
FY Report Date 12 / 2024 Current Year's Estimate 14.528
Last Quarter’s Earnings 3.50 Median PE on CY Estimate N/A
Year Ago Earnings 13.56 Next Fiscal Year Estimate 16.01
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 16 13 18 18
Mean Estimate 3.40 3.87 14.53 16.01
High Estimates 3.52 4.06 14.65 16.90
Low Estimate 3.24 3.59 14.37 15.75
Coefficient of Variance 1.95 3.64 0.44 1.65

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 12 12 10
OVERWEIGHT 2 2 2
HOLD 6 7 6
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Labcorp Holdings - LH

Date Name Shares Transaction Value
May 16, 2024 Sandra Danett van der Vaart EVP, Chief Legal Officer 5,837 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $210.83 per share 1,230,614.71
May 16, 2024 Sandra Danett van der Vaart EVP, Chief Legal Officer 5,637 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $210.84 per share 1,188,505.08
May 3, 2024 Kerrii B. Anderson Director 15,972 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $204.14 per share 3,260,524.08
May 3, 2024 Glenn Andrew Eisenberg Chief Financial Officer, EVP 46,289 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $201.37 per share 9,321,215.93
May 3, 2024 Glenn Andrew Eisenberg Chief Financial Officer, EVP N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 3, 2024 Kerrii B. Anderson Director 15,722 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $200.1 per share 3,145,972.20
May 3, 2024 Glenn Andrew Eisenberg Chief Financial Officer, EVP 50,785 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 2, 2024 Peter J. Wilkinson SVP, Chief Accounting Officer 2,087 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $204.33 per share 426,436.71
Mar 11, 2024 Mark S. Schroeder EVP, Pres Diagnostics & COO 5,036 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $218.45 per share 1,100,114.20
Mar 11, 2024 Mark S. Schroeder EVP, Pres Diagnostics & COO N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2024 Amy B. Summy EVP, Chief Marketing Officer 3,859 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $218.45 per share 842,998.55
Mar 11, 2024 Mark S. Schroeder EVP, Pres Diagnostics & COO 10,084 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $117.09 per share 1,180,735.56
Feb 23, 2024 Jonathan DiVincenzo EVP, Pres, Central Labs & Intl 3,401 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $215.49 per share 732,881.49
Feb 23, 2024 Glenn Andrew Eisenberg Chief Financial Officer, EVP N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 23, 2024 Glenn Andrew Eisenberg Chief Financial Officer, EVP 23,595 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $217.98 per share 5,143,238.10
Feb 23, 2024 Glenn Andrew Eisenberg Chief Financial Officer, EVP 25,148 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $217.52 per share 5,470,192.96
Feb 14, 2024 Adam H. Schechter President & CEO; Director 54,225 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 14, 2024 Adam H. Schechter President & CEO; Director 95,277 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 14, 2024 Adam H. Schechter President & CEO; Director 52,994 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $227.45 per share 12,053,485.30
Feb 14, 2024 Lance V. Berberian EVP, CIO & CTO 23,616 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $227.45 per share 5,371,459.20

Labcorp Holdings in the News